Quick Answer
Editas Medicine, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $40.52 million for the year ending 2025.
- Editas Medicine, Inc. showed an increase of +25.4% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Editas Medicine, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 9 years of available data (2017 to 2025), Editas Medicine, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 195.2%.
- Historical annual values: Fiscal year 2025: $40.52 million | Fiscal year 2024: $32.31 million | Fiscal year 2023: $78.12 million | Fiscal year 2022: $19.71 million | Fiscal year 2021: $25.54 million | Fiscal year 2020: $90.73 million | Fiscal year 2019: $20.53 million | Fiscal year 2018: $31.94 million | Fiscal year 2017: $13.73 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: